Spotlight

Volterrex Launches 4,000 Lumen Configurable LED Pro Lantern

Retrieved on: 
Monday, March 4, 2024
USB, Spotlight, DIY, Recreation, Lighting, MSRP, Environment, Mah, LED, Kerosene

EAST PROVIDENCE, R.I., March 4, 2024 /PRNewswire-PRWeb/ -- Volterrex by ISM Lighting, manufacturer of industrial-grade portable light solutions, today announced the expansion of its line of Prosumer portable LED lighting products with the addition of the Volterrex LED Pro Lantern. Featuring four light settings, the innovative 4,000 lumen LED Pro Lantern illuminates any environment with 360° or 180° light, a Spotlight configuration that casts a beam like a hyper-powerful flashlight, and a Warning Light configuration that pulses a flashing beacon for emergency situations. The portable lamp is the ideal solution for illuminating any environment on the go from home DIY projects to commercial job sites, campsites, and roadside emergencies. For more information on the new Volterrex LED Pro Lantern, please visit: https://volterrex.com/products/lantern.

Key Points: 
  • EAST PROVIDENCE, R.I., March 4, 2024 /PRNewswire-PRWeb/ -- Volterrex by ISM Lighting , manufacturer of industrial-grade portable light solutions, today announced the expansion of its line of Prosumer portable LED lighting products with the addition of the Volterrex LED Pro Lantern .
  • For more information on the new Volterrex LED Pro Lantern, please visit: https://volterrex.com/products/lantern .
  • Its multi-angle handle allows the LED Pro Lantern to be carried as a traditionally slung lantern or as a flashlight, and serves as a stand to position the lantern for exacting light.
  • The Volterrex LED Pro Lantern is available directly at https://volterrex.com/products/lantern .

Vital’s ERAdvisor Earns Top Marks in KLAS Spotlight Report

Retrieved on: 
Thursday, February 15, 2024
Health, Technology, Hospitals, Practice Management, Health Technology, Software, Artificial Intelligence, Hospital, Senior, Research, NPS, Education, Repurchase agreement, ROI, Patient satisfaction, Spotlight, KLAS, Patient, Integration, Trust, Tangibility, Partnership, Nursing

Vital , a leading artificial intelligence-(AI) driven digital health company, today announced that its exceptional performance was featured in a recent KLAS Research Emerging Company Spotlight .

Key Points: 
  • Vital , a leading artificial intelligence-(AI) driven digital health company, today announced that its exceptional performance was featured in a recent KLAS Research Emerging Company Spotlight .
  • KLAS provides in-depth analyses and ratings of healthcare IT software and services that healthcare leaders use to inform purchase and implementation decisions.
  • “The KLAS report reaffirms Vital's position as a leader in digital health and emphasizes the critical role of close collaboration with health system partners,” said Joe Sedlak, Senior Vice President of Client Success at Vital.
  • Exceptional Executive Involvement: With an "A+" rating, Vital demonstrates an unparalleled commitment to partnering with customers, ensuring that ERAdvisor meets and exceeds expectations.

Snap Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 6, 2024
Technology, Advertising, Communications, Social Media, Digital Marketing, Apps, Applications, Photography, Software, Artificial Intelligence, Internet, Content Marketing, User (computing), Maus, NYX, Lens, Cincinnati Bengals, Total, Pixel, MAU, DAU, Shithead (card game), Webcast, NYX Professional Makeup, Seattle Mariners, ChatGPT, Curriculum, IOS, Generative, Depreciation, The Rolling Stones, Spotify, Business, Cosmetics, Growth, Calendar, MTV Video Music Awards, Regulation, Automation, ESPN, Free cash flow, ARPU, Snap Inc., GAAP, Brooklyn Nets, Android, Spotlight, Disclosure, Adjustment, Barclays Center, Regulation Fair Disclosure, Common, Active users, Video game

We grew and deepened our engagement with our community:

Key Points: 
  • We grew and deepened our engagement with our community:
    DAUs were 414 million in Q4 2023, an increase of 39 million, or 10%, year-over-year.
  • Snap Inc. will host a conference call to discuss the results at 3 p.m. Pacific / 6 p.m. Eastern today.
  • We calculate average Monthly Active Users for a particular quarter by calculating the average of the MAUs as of each calendar month-end in that quarter.
  • Note: For adjustments and additional information regarding the non-GAAP financial measures and other items discussed, please see “Non-GAAP Financial Measures,” “Reconciliation of GAAP to Non-GAAP Financial Measures,” and “Supplemental Financial Information and Business Metrics.”

MEDITECH to Showcase What Makes Expanse the Intelligent EHR at HIMSS 2024

Retrieved on: 
Thursday, February 1, 2024
Nursing, Technology, Health, General Health, Pharmaceutical, Oncology, Mental Health, Health Technology, Software, Artificial Intelligence, Clinical Trials, Cloud, Intelligence, Population health, EHR, Kiosk, Link, Health informatics, Avera Health, Cancer Breakthroughs 2020, AI, Clinical trial, Spotlight, Overalls, Safety, Philosophy, Diagnosis, MEDITECH, College, NLP, HIMSS, CIO, Culture, Google Cloud, Humber River Hospital, API, Medicine, HCA Healthcare, Doctor of Philosophy, Face, Organization

Join MEDITECH at HIMSS 2024 , March 11-15 in Orlando, FL, for a comprehensive look at Expanse , the foundational EHR and cornerstone to a collaborative ecosystem.

Key Points: 
  • Join MEDITECH at HIMSS 2024 , March 11-15 in Orlando, FL, for a comprehensive look at Expanse , the foundational EHR and cornerstone to a collaborative ecosystem.
  • MEDITECH executives and product experts will also be showcasing many of the solutions that make MEDITECH the intelligent EHR, including our approach to AI , innovative care models , precision medicine , population health , interoperability , and more.
  • You can also learn about our latest advancements, including Expanse Pathology , ambient listening, and our cloud-based patient portal.
  • Visit MEDITECH’s HIMSS 2024 event page for the latest updates and additional information, including session times and a special customer appreciation event.

AAHA Announces Enhanced Digital Benchmarking Platform – Now Free for All Members

Retrieved on: 
Friday, December 8, 2023
Spotlight, AAHA, Success, CO, Health, Account, PIMS, American Animal Hospital Association, Medicine, FIDO, Veterinary medicine, Health insurance

Lakewood, CO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- The American Animal Hospital Association (AAHA) is proud to partner with Chewy Health to provide its comprehensive analytics platform, AAHA Benchmarking+, free to all members and practices using certain Chewy Health tools.

Key Points: 
  • Lakewood, CO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- The American Animal Hospital Association (AAHA) is proud to partner with Chewy Health to provide its comprehensive analytics platform, AAHA Benchmarking+, free to all members and practices using certain Chewy Health tools.
  • This innovative cloud-based platform replaces AAHA’s printed Vital Stats series in direct response to feedback from AAHA’s members.
  • The FIDO dashboards, the latest addition to the platform, include Fee reference, Inventory, Doctor opportunities, and Optimized employee health.
  • AAHA Benchmarking+ is now free to all AAHA members as well as practices using Chewy Health tools such as PracticeHub.

Licensing International Foundation Honors Pam Kaufman, Cindy Levitt, and Carole Postal at 2023 Hall of Fame Event

Retrieved on: 
Wednesday, December 6, 2023
Pace, PAW Patrol, Mentorship, Rising Star Award, SpongeBob SquarePants, International Foundation, Teenage Mutant Ninja Turtles, Woman, Student, Marketing, Paramount, Female, Greenwich Savings Bank Building, International, Star Trek, Playmates Toys, Education, Globalization, VidCon, Carnival Films, Love, CBS, Inclusion, Growth, SVP, Hot Topic, Public affairs, EVP, Spotlight

NEW YORK, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Licensing International , the leading trade association for the $340+ billion global brand licensing industry, and the Licensing International Foundation , which supports the education of future licensing leaders, today celebrated the induction of Pam Kaufman, Cindy Levitt, and Carole Postal to the Licensing International Hall of Fame.

Key Points: 
  • NEW YORK, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Licensing International , the leading trade association for the $340+ billion global brand licensing industry, and the Licensing International Foundation , which supports the education of future licensing leaders, today celebrated the induction of Pam Kaufman, Cindy Levitt, and Carole Postal to the Licensing International Hall of Fame.
  • Established in 1989, the Licensing International Hall of Fame is home to the most esteemed global licensing executives of the last three decades.
  • In addition to honoring Kaufman, Levitt, and Postal, the 2023 Hall of Fame event recognized rising talent already making strides in the licensing industry.
  • “The impact Pam, Cindy, and Carole have had on the global brand licensing industry cannot be overstated,” said Maura Regan, President of Licensing International.

Hanzo Wins “Best Use of AI for eDiscovery” In 2023 LegalTech Breakthrough Awards Program

Retrieved on: 
Thursday, November 16, 2023
LLM, Data science, Warner Bros. Discovery EMEA, Spotlight, Hanzo (Overwatch), Collection, IBM, Ecosystem, Transparency, Intelligence, Legal technology, Security, HR, Illuminate, API, AI, Use, Pharmaceutical industry, Medical device, Hattori Hanzō

Hanzo Illuminate, powered by Spotlight AI, a fully integrated AI engine, is the market's first tool designed for automated conversational relevancy assessment.

Key Points: 
  • Hanzo Illuminate, powered by Spotlight AI, a fully integrated AI engine, is the market's first tool designed for automated conversational relevancy assessment.
  • Spotlight AI adds a generative AI data intelligence layer to Illuminate’s preservation, collection, culling, and analysis capabilities.
  • “Earning the 'Best Use of AI for eDiscovery' award from LegalTech Breakthrough is not only an honor but also reflects our dedication to applying AI in real-world scenarios.
  • Most importantly, Spotlight AI eschews the "black-box" AI approach, offering users transparent AI-driven decisions that bolster trust and clarity.

Take Control of Your Health in the New Year with Functional Wellness Tests from Designs for Health

Retrieved on: 
Thursday, December 14, 2023
Diet, Medicine, Functional medicine, DNA, Spotlight, Informatics, Genomics, Patient, Single-nucleotide polymorphism, Metabolism, Algorithm, Machine learning, Oxidative stress, Movement, GI, Ageing, Biochemistry, Medicare, Real-time, Nursing, Medicaid, Design, Health

PALM COAST, Fla., Dec. 14, 2023 /PRNewswire/ -- As we gear up for the New Year, Designs for Health, the expert-recommended and preferred brand for high-quality, professional strength, research-backed supplements is making it easier than ever for healthcare practitioners to provide a personalized approach to patient outcomes thanks to its innovative Spotlight functional wellness tests. The three tests, Metabolomics Spotlight, GI Spotlight, and Genomic Spotlight, help inform and guide healthcare practitioners to support their patients' overall optimal health through appropriate diet, lifestyle, and nutraceutical suggestions by assessing their metabolic status, microbiome, or genomic data.

Key Points: 
  • Designs for Health GI Spotlight™ provides an in-depth look into the symbiotic health status of the gut microbiome.
  • It then evaluates eight key areas of health including cellular communication, bone and structural health, cognitive health, detoxification, endocrine health, inflammatory status, GI health, and aging.
  • Designs for Health Spotlight™ testing must be ordered or authorized by a qualified healthcare provider registered with Designs for Health.
  • Designs for Health Spotlight™ tests are not diagnostic and are not eligible for coverage under Medicare, Medicaid, or medical insurance.

Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent

Retrieved on: 
Wednesday, December 13, 2023
Woman, Safety, SAN, Toxicity, Drainage, Breast cancer, Spotlight, Clinical trial, Patient, Lymph, ASX, Investigational New Drug, Conference, HER2, MRI, Parity, Radiology, Medical imaging

Thirteen women definitively diagnosed with HER2+ breast cancer were enrolled and treated with the drug without any safety issues, toxicity or drug-related adverse events reported.

Key Points: 
  • Thirteen women definitively diagnosed with HER2+ breast cancer were enrolled and treated with the drug without any safety issues, toxicity or drug-related adverse events reported.
  • Too many of these women endure unnecessary interventions that provide incomplete information and impose unnecessary costs on global healthcare systems.
  • The IBI10103 clinical trial was closed in October 2023 and evaluated the potential of the world's first molecularly targeted MRI contrast agent, MSH2IA (MagSense® HER2 Imaging Agent), to enhance clinicians' ability to non-invasively and more accurately determine the stage of HER2+ breast cancer.
  • Importantly, MRI assessment of post-MSH2IA imaging achieved parity or outperformed standard-of-care axillary ultrasound imaging in all 8 of these patients.

Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent

Retrieved on: 
Wednesday, December 13, 2023
Woman, Safety, SAN, Toxicity, Drainage, Breast cancer, Spotlight, Clinical trial, Patient, Lymph, ASX, Investigational New Drug, Conference, HER2, MRI, Parity, Radiology, Medical imaging

Thirteen women definitively diagnosed with HER2+ breast cancer were enrolled and treated with the drug without any safety issues, toxicity or drug-related adverse events reported.

Key Points: 
  • Thirteen women definitively diagnosed with HER2+ breast cancer were enrolled and treated with the drug without any safety issues, toxicity or drug-related adverse events reported.
  • Too many of these women endure unnecessary interventions that provide incomplete information and impose unnecessary costs on global healthcare systems.
  • The IBI10103 clinical trial was closed in October 2023 and evaluated the potential of the world's first molecularly targeted MRI contrast agent, MSH2IA (MagSense® HER2 Imaging Agent), to enhance clinicians' ability to non-invasively and more accurately determine the stage of HER2+ breast cancer.
  • Importantly, MRI assessment of post-MSH2IA imaging achieved parity or outperformed standard-of-care axillary ultrasound imaging in all 8 of these patients.